[go: up one dir, main page]

BRPI0415389A - método in vitro para diagnóstico de funcionalidade cardiovascular de células precursoras da medula-óssea (bmps) e/ou células precursoras em circulação derivadas de sangue (bdps) - Google Patents

método in vitro para diagnóstico de funcionalidade cardiovascular de células precursoras da medula-óssea (bmps) e/ou células precursoras em circulação derivadas de sangue (bdps)

Info

Publication number
BRPI0415389A
BRPI0415389A BRPI0415389-8A BRPI0415389A BRPI0415389A BR PI0415389 A BRPI0415389 A BR PI0415389A BR PI0415389 A BRPI0415389 A BR PI0415389A BR PI0415389 A BRPI0415389 A BR PI0415389A
Authority
BR
Brazil
Prior art keywords
precursor cells
bdps
bmps
bone marrow
vitro method
Prior art date
Application number
BRPI0415389-8A
Other languages
English (en)
Inventor
Andreas M Zeiher
Christopher Heeschen
Stefanie Dimmeler
Original Assignee
Johann Wolfgang Goethe Univers
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Johann Wolfgang Goethe Univers filed Critical Johann Wolfgang Goethe Univers
Publication of BRPI0415389A publication Critical patent/BRPI0415389A/pt

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56966—Animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K2035/124—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells the cells being hematopoietic, bone marrow derived or blood cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70589—CD45
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70596—Molecules with a "CD"-designation not provided for elsewhere in G01N2333/705
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/745—Assays involving non-enzymic blood coagulation factors
    • G01N2333/755—Factors VIII, e.g. factor VIII C [AHF], factor VIII Ag [VWF]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Zoology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • General Engineering & Computer Science (AREA)

Abstract

"MéTODO IN VITRO PARA DIAGNóSTICO DE FUNCIONALIDADE CARDIOVASCULAR DE CéLULAS PRECURSORAS DA MEDULA-óSSEA (BMPs) E/OU CéLULAS PRECURSORAS EM CIRCULAçãO DERIVADAS DE SANGUE (BDPs)". A presente invenção refere-se a um método in vitro para a análise de uma amostra de um mamífero em conexão com doenças cardiovasculares, onde o método compreende as etapas que seguem: a) isolamento de células precursoras de medula-óssea (BMPs) e/ou células precursoras de circulação derivadas de sangue (BDPs) por meio de marcadores de superfície específicos de célula, e b) detecção da funcionalidade cardiovascular das BMPs e/ou BDPs isoladas por meio de um ensaio de migração adequado. O método de acordo com a invenção pode ser empregado como um kit no contexto do diagnóstico e/ou prognóstico de doenças cardiovasculares, para o monitoramento de suas terapias e/ou para a estratificação para uma terapia de célula prospectiva com células tronco e/ou precursoras a fim de aumentar a perfusão de tecido isquêmico ou para a regeneração de perdas de tecido (por exemplo, insuficiência cardíaca), respectivamente. Em um aspecto adicional, a presente invenção refere-se então a um método in vitro para isolamento de células precursoras da medula-óssea específicas por meio de um ensaio de migração adequado. De acordo com a invenção, essas BMPs e/o BDPs podem ser usadas para o tratamento de doenças cardiovasculares, selecionadas do grupo consistindo em doença cardíaca coronária, síndrome coronária aguda, infarto do miocárdio agudo, cardiomiopatia isquêmica crónica (ICMP), cardiomiopatia dilatativa (DCM) ou outras causas para uma insuficiência cardíaca.
BRPI0415389-8A 2003-10-13 2004-10-13 método in vitro para diagnóstico de funcionalidade cardiovascular de células precursoras da medula-óssea (bmps) e/ou células precursoras em circulação derivadas de sangue (bdps) BRPI0415389A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10347436A DE10347436B4 (de) 2003-10-13 2003-10-13 In vitro Verfahren zur Diagnose der kardiovaskulären Funktionalität von Blut-abgeleiteter zirkulierender Vorläuferzellen (BDP)
PCT/EP2004/011503 WO2005038454A1 (de) 2003-10-13 2004-10-13 In vitro verfahren zur diagnose der kardiovaskulären funktionalität von knochenmarks-vorläuferzellen (bmp) und/oder blut-abgeleiteter zirkulierender vorläuferzellen (bdp)

Publications (1)

Publication Number Publication Date
BRPI0415389A true BRPI0415389A (pt) 2006-12-12

Family

ID=34441894

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0415389-8A BRPI0415389A (pt) 2003-10-13 2004-10-13 método in vitro para diagnóstico de funcionalidade cardiovascular de células precursoras da medula-óssea (bmps) e/ou células precursoras em circulação derivadas de sangue (bdps)

Country Status (18)

Country Link
US (1) US7919315B2 (pt)
EP (1) EP1673629B1 (pt)
JP (1) JP2007511206A (pt)
KR (1) KR20070026319A (pt)
CN (1) CN1867827A (pt)
AT (1) ATE477484T1 (pt)
AU (1) AU2004282647A1 (pt)
BR (1) BRPI0415389A (pt)
CA (1) CA2551049A1 (pt)
DE (2) DE10347436B4 (pt)
DK (1) DK1673629T3 (pt)
EA (1) EA200600613A1 (pt)
ES (1) ES2350581T3 (pt)
IL (1) IL174903A0 (pt)
MX (1) MXPA06004101A (pt)
NO (1) NO20062160L (pt)
WO (1) WO2005038454A1 (pt)
ZA (1) ZA200602982B (pt)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1522857A1 (en) * 2003-10-09 2005-04-13 Universiteit Maastricht Method for identifying a subject at risk of developing heart failure by determining the level of galectin-3 or thrombospondin-2
ES2532909T3 (es) 2004-07-30 2015-04-01 Mayo Foundation For Medical Education And Research Tratamiento de tejido cardiovascular
US8637005B2 (en) 2005-11-07 2014-01-28 Amorcyte, Inc. Compositions and methods of vascular injury repair
US20110076255A1 (en) 2005-11-07 2011-03-31 Pecora Andrew L Compositions and methods for treating progressive myocardial injury due to a vascular insufficiency
US9765298B2 (en) 2006-07-24 2017-09-19 Mayo Foundation For Medical Education And Research Methods and materials for providing cardiac cells
CN101536006A (zh) 2006-11-10 2009-09-16 皇家飞利浦电子股份有限公司 用于患者医疗的治疗计划的设备、方法、计算机可读介质
AT506041A1 (de) * 2007-12-10 2009-05-15 Univ Innsbruck Verfahren zur erhöhung der immunreaktivität
WO2009145761A1 (en) 2008-05-27 2009-12-03 Mayo Foundation For Medical Education And Research Methods and materials for using cells to treat heart tissue
EP2359143A1 (en) * 2008-10-29 2011-08-24 BG Medicine, Inc. Galectin-3 immunoassay
ES2640587T3 (es) * 2008-12-03 2017-11-03 Amorcyte, Inc. Composición mejorada de la perfusión en una zona de infarto
CA2761807C (en) * 2009-05-20 2018-01-09 Mayo Foundation For Medical Education And Research Method for determining the cardio-generative potential of mammalian cells
CN102576028A (zh) * 2009-08-25 2012-07-11 保函医药公司 半乳凝集素-3和心脏再同步疗法
DE102009042160B3 (de) * 2009-09-11 2011-04-14 Eberhard-Karls-Universität Tübingen Universitätsklinikum Verfahren zur Diagnose und/oder Vorhersage der Entwicklung von neurodegenerativen Erkrankungen
KR101939778B1 (ko) 2012-07-27 2019-01-18 삼성전자주식회사 필요 혈류량 결정 방법 및 장치, 혈류 영상 생성 방법 및 장치, 심근 관류 영상 처리 방법 및 장치
CN105286819B (zh) * 2015-12-03 2018-08-07 北京大学人民医院 一种辅助判断全人群血管功能的试剂盒
DE102017116204B4 (de) 2017-07-18 2024-06-27 Universität Rostock Verfahren zur Vorhersage der Antwort auf die kardiovaskuläre Regeneration

Also Published As

Publication number Publication date
DK1673629T3 (da) 2010-12-06
KR20070026319A (ko) 2007-03-08
ZA200602982B (en) 2007-07-25
DE10347436A1 (de) 2005-05-19
AU2004282647A1 (en) 2005-04-28
WO2005038454A1 (de) 2005-04-28
DE502004011526D1 (de) 2010-09-23
EP1673629B1 (de) 2010-08-11
ATE477484T1 (de) 2010-08-15
EP1673629A1 (de) 2006-06-28
CA2551049A1 (en) 2005-04-28
US7919315B2 (en) 2011-04-05
JP2007511206A (ja) 2007-05-10
US20070274959A1 (en) 2007-11-29
ES2350581T3 (es) 2011-01-25
IL174903A0 (en) 2006-08-20
NO20062160L (no) 2006-06-23
MXPA06004101A (es) 2007-03-26
DE10347436B4 (de) 2007-08-02
EA200600613A1 (ru) 2006-10-27
CN1867827A (zh) 2006-11-22

Similar Documents

Publication Publication Date Title
IL174903A0 (en) IN VITRO METHOD FOR THE DIAGNOSIS OF CARDIOVASCULAR FUNCTIONALITY OF BONE MARROW-PRECURSOR CELLS (BMPs) AND/OR BLOOD DERIVED CIRCULATING PRECURSOR CELLS (BDPS)
Reiser et al. Human cardiac myosin heavy chain isoforms in fetal and failing adult atria and ventricles
McKie et al. B-type natriuretic peptide as a biomarker beyond heart failure: speculations and opportunities
Cracowski et al. The potential of biomarkers in pulmonary arterial hypertension
Zhao et al. Circulating irisin is lower in gestational diabetes mellitus
Boo et al. Comparison of serum cardiac troponin T and creatine kinase MB isoenzyme mass concentrations in asphyxiated term infants during the first 48 h of life
Cavus et al. Heart-type, fatty-acid binding protein can be a diagnostic marker in acute coronary syndromes
CA2509063A1 (en) Scd40l and placental growth factor (plgf) as biochemical marker combinations in cardiovascular diseases
Gururajan et al. Heart fatty acid binding protein (H-FABP) as a diagnostic biomarker in patients with acute coronary syndrome
Özcan et al. Increased level of resistin predicts development of atrial fibrillation
La Salvia et al. Extracellular vesicles in essential hypertension: hidden messengers
Ferratini et al. Pentraxin-3 predicts functional recovery and 1-year major adverse cardiovascular events after rehabilitation of cardiac surgery patients
Niebroj-Dobosz et al. Circulating tenascin-C levels in patients with dilated cardiomyopathy in the course of Emery-Dreifuss muscular dystrophy
Ostermann et al. Biomarker-based management of AKI: fact or fantasy?
Lorin et al. Increased symmetric dimethylarginine level is associated with worse hospital outcomes through altered left ventricular ejection fraction in patients with acute myocardial infarction
Gąsecka et al. Plasma concentration of TMAO is an independent predictor of adverse outcomes in patients after acute myocardial infarction
Eleuteri et al. Fibrosis markers and CRIM1 increase in chronic heart failure of increasing severity
Ai et al. Reduced vitamin D receptor on circulating endothelial progenitor cells: a new risk factor of coronary artery diseases
Israr et al. Surrogate markers of gut dysfunction are related to heart failure severity and outcome–from the BIOSTAT-CHF consortium
Pei et al. Serum cystatin C, klotho, and neutrophil gelatinase-associated lipocalin in the risk prediction of acute kidney injury after acute myocardial infarction
Zhang et al. Urinary modified nucleosides as novel biomarkers for diagnosis and prognostic monitoring of urothelial bladder cancer
Gaggar et al. Biologic markers of mortality in acute lung injury
CN116256523B (zh) 生物标志物在制备用于糖尿病患者HFpEF检测试剂中的应用
Kawai et al. Clinical usefulness of malate dehydrogenase and its mitochondrial isoenzyme in comparison with aspartate aminotransferase and its mitochondrial isoenzyme in sera of patients with liver disease
Alkhiary et al. Serum Concentrations of interleukin-33 and its soluble receptor sST2 in patients with persistent atrial fibrillation

Legal Events

Date Code Title Description
B11A Dismissal acc. art.33 of ipl - examination not requested within 36 months of filing
B11Y Definitive dismissal - extension of time limit for request of examination expired [chapter 11.1.1 patent gazette]
B15K Others concerning applications: alteration of classification

Free format text: PROCEDIMENTO AUTOMATICO DE RECLASSIFICACAO. AS CLASSIFICACOES IPC ANTERIORES ERAM: G01N 33/50; C12N 5/06.

Ipc: G01N 33/569 (2006.01), G01N 33/50 (2006.01), A61K

Ipc: G01N 33/569 (2006.01), G01N 33/50 (2006.01), A61K